Method
Level · gp.fundamentals.debt_to_revenue
Raw value 163.92% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTPTC THERAPEUTICS, INC.'s latest supported as-filed period reports revenue of $360.5M, 101.5% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 163.92% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.61% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 35.81% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 101.55% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 25.34% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 41.32% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +3.2% from the comparable as-filed period.
Inventory changed +168.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Net income changed +228.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
PTCT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001288952-26-000004SEC ↗4Aug 19, 2026Period Aug 17, 20260001578852-26-000022SEC ↗8-KAug 13, 2026Period Aug 12, 20260001104659-26-095424SEC ↗4Aug 6, 2026Period Aug 4, 20260001808968-26-000017SEC ↗4Jul 30, 2026Period Jul 28, 20260002142653-26-000004SEC ↗10-QJul 30, 2026Period Jun 30, 20260001070081-26-000017SEC ↗8-KJul 30, 2026Period Jul 28, 20260001070081-26-000016SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026Filed Aug 21, 2026 | SCHMERTZLER MICHAELDirector | Open Market SaleIndirect | 9,419 | $71 | $666,677 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 21, 2026 | SCHMERTZLER MICHAELDirector | Open Market SaleIndirect | 2,390 | $72 | $171,793 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 21, 2026 | SCHMERTZLER MICHAELDirector | Open Market SaleIndirect | 691 | $73 | $50,388 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | SCHMERTZLER MICHAELDirector | Open Market SaleIndirect | 5,335 | $73 | $388,708 | Form 4 ↗ |
| Aug 19, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 27.50% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 6.46% · OPTIONAL
Operating income changed +526.2% from the comparable as-filed period.
Operating margin changed +6087 basis points from the comparable as-filed period.
Research & development changed -12.2% from the comparable as-filed period.
Revenue changed +101.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001984065-26-000008| SCHMERTZLER MICHAELDirector |
| Open Market SaleIndirect |
| 7,165 |
| $74 |
| $527,846 |
| Form 4 ↗ |